Human Fas ligand extracellular domain: current status of biochemical characterization, engineered-derivatives production, and medical applications. 2022. 9. 4. 467-485
Michiro Muraki. Soluble Fas ligand, soluble Fas receptor, and decoy receptor 3 as disease biomarkers for clinical applications: A review. AIMS Medical Science. 2022. 9. 2. 98-267
Michiro Muraki. Sensitization to cell death induced by soluble Fas ligand and agonistic antibodies with exogenous agents: A review. AIMS Medical Science. 2020. 7. 3. 122-203
Michiro Muraki, Kiyonori Hirota. Site-specific biotin-group conjugate of human Fas ligand extracellular domain: preparation and characterization of cell-death-inducing activity. Current Topics in Peptide & Protein Research. 2019. 20. 17-24
M Muraki, N Sugita, K Sato, K Harata. Inactivation of lysozyme by 2',3'-epoxypropyl-beta-glycoside derivatives of Gal-beta-(1->4)-GlcNAc and Man-beta-(1->4)-GlcNAc. PROTEIN ENGINEERING. 1996. 9. 9. 28-28
M. Muraki, S. Goda, H. Nagahora, K. Harata. IMPORTANCE OF GLUTAMIC ACID 35-TRYPTOPHAN 109 CONTACT IN THE MAINTENANCE OF THE CATALYTIC CLEFT GEOMETRY OF HUMAN LYSOZYME. ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES. 1996. 52. C197-C197
M MURAKI, Y JIGAMI. INTERMOLECULAR CROSS-LINKING OF HUMAN LYSOZYME USING A CYSTEINE RESIDUE INTRODUCED BY SITE-DIRECTED MUTAGENESIS. PROTEIN ENGINEERING. 1994. 7. 9. 1167-1167